

<p>Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., Fujisaka, Y., Philips, J., Shimizu, T., Maenishi, O., Cho, Y., Sun, J., Destro, A., Taira, K., <u>Takeda, K.</u>, Okabe, T., Swanson, J., Itoh, H., Takada, M., Lifshits, E., Okuno, K., Engelman, JA., Shivdasani, RA., Nishio, K., Fukuoka, M., Varella-Garcia, M., <u>Nakagawa, K.</u>, Jänne, PA.</p>	<p>Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab</p>	<p>Sci Transl Med</p>	<p>3(99)</p>	<p>99ra86</p>	<p>2011</p>
<p>Tanizaki, J., Okamoto, I., Sakai, K., <u>Nakagawa, K.</u></p>	<p>Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification</p>	<p>British Journal of Cancer</p>	<p>105(6)</p>	<p>807-13</p>	<p>2011</p>
<p>Osoegawa, A., Kometani, T., Nosaki, K., Ondo, K., Hamatake, M., Hirai, F., <u>Seto, T.</u>, Sugio, K., Ichinose Y.</p>	<p>LKB1 mutations frequently detected in mucinous bronchioloalveolar carcinoma</p>	<p>Jpn J Clin Oncol</p>	<p>41</p>	<p>1132-37</p>	<p>2011</p>
<p>Ohba, T., Sugio, K., Kometani, T., Yamaguchi, M., Hamatake, M., Nosaki, K., Takeoka, H., Kitajima, H., Hirai, F., <u>Seto, T.</u>, Taguchi, K., Nishiyama, K., Shida, Y., Ichinose, Y.</p>	<p>Signet ring cell adenocarcinoma of the lung with an EML4-ALK fusion gene mimicking mucinous (colloid) adenocarcinoma: a case report</p>	<p>Lung Cancer</p>	<p>73</p>	<p>375-78</p>	<p>2011</p>

<p>Tanaka, H., Kimura, T., <u>Kudoh, S.</u>, Mitsuoka, S., Watanabe, T., Suzumura, T., Tachibana, K., Noguchi, M., Yano, S., Hirata, K.</p>	<p>Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs</p>	<p>Int J Cancer</p>	<p>129(6)</p>	<p>1410-16</p>	<p>2011</p>
<p>Imamura, F., Nishio, M., Noro, R., Tsuboi, M., Ikeda, N., Inoue, A., Ohsaki, Y., Kimura, Y., Nishino, K., Uchida, J., Horai, T.</p>	<p>Randomized Phase II Study of Two Schedules of Carboplatin and Gemcitabine for Stage IIIB and IV Advanced Non-Small Cell Lung Cancer (JACCRO LC-01 Study)</p>	<p>Chemotherapy</p>	<p>57(4)</p>	<p>357-62</p>	<p>2011</p>
<p><u>Hirashima, T.</u>, Suzuki, H., Kobayashi, M., Kondoh, Y., Tokuoka, Y., Matsuura, Y., Tamiya, M., MorishiTa, N., Sasada, S., Okamoto, N., Akazawa, K., Kawase, I.</p>	<p>Long-term chemotherapy may Prolong survival in advanced non-small-cell lung cancer among responders to first-line Chemotherapy</p>	<p>Medical Oncology</p>			<p>2011 [Epub ahead of print]</p>
<p>Naoki, K., Soejima, K., <u>Okamoto, H.</u>, Hamamoto, J., Hida, N., Nakachi, I., Yasuda, H., Nakayama, S., Yoda, S., Satomi, R., Ikemura, S., Terai, H., Sato, T., Watanabe, K.</p>	<p>The PCR-invader method (structure-specific 5' nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing</p>	<p>Int J Clin Oncol</p>	<p>16</p>	<p>335-44</p>	<p>2011</p>

<p>Kobayashi, M., Matsui, K., Katakami, N., <u>Takeda, K.</u>, Moriyama, A., Iwamoto, Y., Takada, M., Yoshioka, H., Sueoka, N., <u>Nakagawa, K.</u> for the West Japan Oncology Group.</p>	<p>Phase II Study of Gefitinib as aFirst-line Therapy in Elderly Patients with Pulmonary Adenocarcinoma: West Japan Thoracic Oncology Group Study 0402</p>	<p>Jpn J Clin Oncol</p>	<p>41(8)</p>	<p>948-52</p>	<p>2011</p>
<p>Kawakami, H., Sugioka, K., Yonesaka, K., Satoh, T., Shimomura, Y., <u>Nakagawa, K.</u></p>	<p>Human epidermal growth factor eyedrops for cetuximab-related filamentary keratitis</p>	<p>J Clin Oncol</p>	<p>29(23)</p>	<p>678-79</p>	<p>2011</p>
<p>Lara, PN Jr., Douillar, JY., <u>Nakagawa, K.</u>, Von Pawel, J., McKeage, MJ., Albert, I., Losonczy, G., Reck, M., Heo, DS., Fan, X., Fandi, A., Scagliotti, G.</p>	<p>Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer</p>	<p>J Clin Oncol</p>	<p>29(22)</p>	<p>2965-71</p>	<p>2011</p>
<p>Asami, K., Kawahara, M., <u>Atagi, S.</u>, Kawaguchi, T., Okishio, K.</p>	<p>Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib</p>	<p>Lung Cancer</p>	<p>73</p>	<p>211-16</p>	<p>2011</p>

<p>Kozu, Y., Tsuta, K., Kohno, T., Sekine, I., Yoshida, A., Watanabe, S., Tamura, T., Yokota, J., Suzuki, K., Asamura, H., Furuta, K., Tsuda, H.</p>	<p>The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma</p>	<p>Lung Cancer</p>	<p>73</p>	<p>45-50</p>	<p>2011</p>
<p>Takahashi, T., <u>Yamamoto, N.</u>, Tamura, T., Kunitoh, H., Nishiwaki, Y., Negoro, S.</p>	<p>Pharmacokinetic and pharmacodynamic profiles of subcutaneous administration of continuous erythropoietin receptor activator in lung cancer patients with anemia induced by chemotherapy</p>	<p>Oncol Lett</p>	<p>2</p>	<p>1033-40</p>	<p>2011</p>
<p>Kenmotsu, H., Naito, T., Kimura, M., Ono, A., Shukuya, T., Nakamura, Y., Tsuya, A., Kaira, K., Murakami, H., Takahashi, T., Endo, M., <u>Yamamoto, N.</u></p>	<p>The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer</p>	<p>J Thorac Oncol</p>	<p>6(7)</p>	<p>1242-46</p>	<p>2011</p>
<p>Fukuoka, M., Wu, YL., Thongprasert, S., Sunpaweravong, P., Leong, SS., Sriuranpong, V., Chao, TY., <u>Nakagawa, K.</u>, Chu, DT., <u>Saijo, N.</u>, Duffield, EL., Rukazenzov, Y., Speake, G., Jiang, H., Armour, AA., To, KF., Yang, JC., Mok, TS.</p>	<p>Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)</p>	<p>J Clin Oncol</p>	<p>29(21)</p>	<p>2866-74</p>	<p>2011</p>

Takeda, M., Okamoto, I., Hirabayashi, N., Kitano, M., <u>Nakagawa, K.</u>	Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer	Lung Cancer	73(1)	103-09	2011
Ogawa, S., Horio, Y., Yatabe, Y., Fukui, T., Ito, S., Hasegawa, Y., Mitsudomi, T., <u>Hida, T.</u>	Patterns of recurrence and outcome in patients with surgically resected small cell lung cancer	Int J Clin Oncol			in press
Tada, T., Chiba, Y., Tsujino, K., Fukuda, H., Nishimura, Y., Kokubo, M., Negoro, S., <u>Kudoh, S.</u> , Fukuoka, M., <u>Nakagawa, K.</u> , Nakanishi, Y.	A Phase I Study of Chemoradiotherapy with Use of Involved-Field Conformal Radiotherapy and Accelerated Hyperfractionation for Stage III Non-Small-Cell Lung Cancer: WJTOG 3305	Int J Radiat Oncol Biol Phys			2011 [Epub ahead of print]
Tamiya, M., Sasada, S., Kobayashi, M., Uehara, N., Okamoto, N., Morishita, N., Suzuki, H., <u>Hirashima, T.</u> , Kawahara, K., Kawase, I.	Diagnostic Factors of Standard Bronchoscopy for Small(≤ 15 mm) Peripheral Pulmonary Lesions: A Multivariate Analysis	Intern Med	50	557-61	2011

Okamoto, I., <u>Yamamoto, N.</u> , Kubota, K., Ohe, Y., <u>Nogami, N.</u> , Murakami, H., Yamaya, H., Ono, K., <u>Nakagawa, K.</u>	Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer	Invest New Drugs			2011, [in press]
Harada, H., <u>Seto, T.</u> , Igawa, S., Tsuya, A., Wada, M., Kaira, K., Naito, T., Hayakawa, K., Nishimura, T., Masuda, N., <u>Yamamoto, N.</u>	Phase I results of vinorelbine with concurrent radiotherapy in elderly patients with unresectable locally-advanced non-small cell lung cancer (NSCLC); West Japan Thoracic Oncology Group WJTOG 3005-D1	Int J Radiat Oncol Biol Phys			2011 [Epub ahead of print]
Kaira, K., Okumura, T., Ohde, Y., Takahashi, T., Murakami, H., Oriuchi, N., Endo, M., Kondo, H., Nakajima, T., <u>Yamamoto, N.</u>	Correlation between 18F-FDG Uptake on PET and Molecular Biology in Metastatic Pulmonary Tumors	J Nucl Med	52(5)	705-11	2011
Shukuya, T., Takahashi, T., Kaira, R., Ono, A., Nakamura, Y., Tsuya, A., Kenmotsu, H., Naito, T., Kaira, K., Murakami, H., Endo, M., Takahashi, K., <u>Yamamoto, N.</u>	The efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring EGFR mutations: A pooled analysis of published reports	Cancer Sci	102(5)	1032-37	2011

Ohyanagi, F., Horai, T., Sekine, I., Yamamoto, N., <u>Nakagawa, K.</u> , <u>Nishio, M.</u> , Senger, S., Morsli, N., Tamura, T.	Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a Phase I/II study	Jpn J Clin Oncol	41(5)	718-22	2011
Fukutomi, A., Hatake, K., Matsui, K., Sakajiri, S., Hirashima, T., Tanii, H., Kobayashi, K., <u>Yamamoto, N.</u>	A phase I study of oral panobinostat(LBH589) in Japanese patients with advanced solid tumors	Invest NewDrugs			2011 [Epub ahead of print]
Suyama, K., Naito, Y., Yoh, K., Niho, S., <u>Goto, K.</u> , Ohmatsu, H., Nishiwaki, Y., Ohe, Y.	Development of Cushing's syndrome during effective chemotherapy for small cell lung cancer	Intern Med	50(4)	335-38	2011
Niho, S., Kubota, K., Yoh, K., <u>Goto, K.</u> , Ohmatsu, H., Nihei, K., Ohe, Y., Nishiwaki, Y.	Clinical outcome of small cell lung cancer with pericardial effusion but without distant metastasis	J Thorac Oncol	6(4)	796-800	2011

<p>Yamada, K., Yamamoto, N., Yamada, Y., Nokihara, H., Fujiwara, Y., Hirata, T., Koizumi, F., Nishio, K., Koyama, N., Tamura, T.</p>	<p>Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors</p>	<p>Clin Cancer Res</p>	<p>17</p>	<p>2528-37</p>	<p>2011</p>
<p><u>Hida, T.</u>, Tamiya, M., <u>Nishio, M.</u>, Yamamoto, N., Hirashima, T., Horai, T., Tani, H., Shi, MM., Kobayashi, K., Horio, Y.</p>	<p>Phase I study of intraven ASA404(vadimezan) administered in combinat paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer</p>	<p>Cancer Sci</p>	<p>102(4)</p>	<p>845-51</p>	<p>2011</p>
<p>Takezawa, K., Okamoto, I., Nishio, K., Janne, P., <u>Nakagawa, K.</u></p>	<p>Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer</p>	<p>Clinical Cancer Research</p>	<p>17(8)</p>	<p>2140-48</p>	<p>2011</p>

Ⅲ. 研究成果の刊行物・別刷

研究代表者	後藤 功一	国立がん研究センター東病院
研究分担者	田村 友秀	国立がん研究センター中央病院
	森 清志	栃木県立がんセンター
	岡本 浩明	横浜市立市民病院
	山本 信之	静岡県立静岡がんセンター
	横山 晶	新潟県立がんセンター新潟病院
	樋田 豊明	愛知県がんセンター中央病院
	今村 文生	大阪府立成人病センター
	平島 智徳	大阪府立呼吸器・アレルギー医療センター
	中川 和彦	近畿大学医学部
	武田 晃司	大阪市立総合医療センター
	木浦 勝行	岡山大学大学院医歯薬学総合研究科
	安宅 信二	近畿中央胸部疾患センター
	里内美弥子	兵庫県立がんセンター
	西條 長宏	近畿大学医学部
	瀬戸 貴司	九州がんセンター
	工藤 新三	大阪市立大学大学院医学研究科
	湊 浩一	群馬県立がんセンター
	澤 祥幸	岐阜市民病院
	西尾 誠人	がん研究会有明病院
	野上 尚之	四国がんセンター

Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer

Tateaki Naito, MD, PhD,* Fumihiko Tanaka, MD, PhD,† Akira Ono, MD,* Kazue Yoneda, BS,‡
Toshiaki Takahashi, MD, PhD,* Haruyasu Murakami, MD, PhD,* Yukiko Nakamura, MD,*
Asuka Tsuya, MD, PhD,* Hirotsugu Kenmotsu, MD,* Takehito Shukuya, MD,*
Kyoichi Kaira, MD, PhD,§ Yasuhiro Koh, MD,|| Masahiro Endo, MD, PhD,¶
Seiki Hasegawa, MD, PhD,‡ and Nobuyuki Yamamoto, MD, PhD*

Background: Enumeration of circulating tumor cells (CTCs) may be valuable for prognostic assessment in lung cancer patients. In this study, we report the clinical significance of CTCs in small cell lung cancer (SCLC).

Methods: In total, 51 consecutive patients newly diagnosed as having SCLC and starting chemotherapy or chemoradiotherapy were prospectively enrolled. Blood samples were drawn at the baseline, after chemotherapy, and at relapse. CTCs were isolated using the CellSearch System (Veridex LLC). Thresholds of 1 to 100 cells at the baseline were systematically correlated with the overall survival. The optimal cutoff was determined by comparing the Cox proportional hazard ratios (HRs).

Results: Two or more CTCs were detected at baseline in 35 patients (68.6%; 95% confidence interval, 55.0–79.7). The HR signifying the difference between the unfavorable (more than or equal to threshold) and favorable (less than threshold) groups was maximal at the threshold of 8 CTCs (HR, 3.50; 95% confidence interval, 1.45–8.60). Patients with ≥ 8 CTCs had worse survival than those with < 8 CTCs at baseline ($p = 0.0014$). Patients with ≥ 8 CTCs posttreatment or at relapse also showed worse survival than those with < 8 CTCs ($p = 0.0096$ and < 0.0001). Patients whose baseline and posttreatment CTC levels remained < 8 tended to show better survival than those whose CTC level converted from ≥ 8 to < 8 cells ($p = 0.0288$) or whose posttreatment CTC level was ≥ 8 cells ($p = 0.0047$).

Conclusions: CTCs were highly detectable in SCLC, and higher CTC levels were strongly associated with worse survival. Consistently favorable CTC levels were associated with favorable outcomes.

Key Words: Circulating tumor cells, Small cell lung cancer, Prognosis.

(*J Thorac Oncol.* 2012;7: 512–519)

Small cell lung cancer (SCLC) accounts for 15% of all lung cancer diagnoses and is characterized by aggressive tumor growth, often presenting with metastases in the regional lymph nodes and distant organs. Because SCLC is highly sensitive to chemotherapy and radiotherapy, early diagnosis followed by appropriate treatment can be expected to yield favorable outcomes.^{1,2} Circulating tumor cells (CTCs) are known to circulate in the peripheral blood in patients with several types of malignancies,^{3–6} while rarely being detected (0.3–1.0%) in healthy control subjects or patients with non-malignant diseases.^{3,7,8} The CellSearch system (Veridex LLC, Raritan, NJ) is a well-validated system for quantitative evaluation of CTCs, in which CTCs are immunomagnetically captured using an antibody against epithelial cell adhesion molecules (EpCAMs).^{9,10} A growing body of evidence suggests the existence of a correlation between CTC level as measured by the CellSearch system and the progression-free survival (PFS) and overall survival (OS) in patients with metastatic breast, colorectal, castration-resistant prostate, and non-small cell lung cancers (NSCLC).^{7,11–15} In SCLC, the detection rate of CTCs by the Cell Search system has been reported to be relatively high, with 67 to 86% of the patients being reported to have ≥ 2 CTCs per 7.5 ml of blood.^{8,16,17} However, the prognostic impact of CTCs and their relationship to the presence of metastases in patients with SCLC remain unknown. We conducted this study to evaluate the relationship of CTC levels to the disease extent and prognosis and to determine the optimal CTC level cutoff for predicting the outcomes in SCLC patients.

METHODS

Study Design

This prospective study was conducted at two institutions (Shizuoka Cancer Center and Hyogo College of Medicine) to evaluate the usefulness of measurement of the CTC

*Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka Prefecture; †Second Department of Surgery, University of Occupational and Environmental Health, Fukuoka Prefecture; ‡Department of Thoracic Surgery, Hyogo College of Medicine, Hyogo Prefecture; §Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Gunma Prefecture; ||Division of Drug Discovery and Development, Shizuoka Cancer Center Research Institute, Shizuoka Prefecture; and ¶Division of Diagnostic Radiology, Shizuoka Cancer Center, Shizuoka Prefecture, Japan.

Disclosure: The authors declare no conflicts of interest.

Address for correspondence: Nobuyuki Yamamoto, MD, PhD, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimnagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan. E-mail: n.yamamoto@schr.jp

Copyright © 2012 by the International Association for the Study of Lung Cancer

ISSN: 1556-0864/12/0703-0512

levels for predicting the OS. Patients with chemotherapy-naïve, pathologically confirmed SCLC scheduled to commence first-line standard chemotherapy with or without thoracic radiotherapy were eligible. All patients were enrolled at the Shizuoka Cancer Center and had an Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 to 2. The institutional review boards at each center approved the study protocol, and all patients provided written informed consent. Before the start of the new treatment, the patients underwent an evaluation of metastatic sites by means of standard imaging studies, including contrast-enhanced computed tomography of the chest to lower abdomen, contrast-enhanced magnetic resonance imaging of the brain, and bone scan or positron emission tomography, along with the collection of blood sampled for counting of the baseline CTCs. The post-treatment blood samples were collected 3 weeks after completion of the last chemotherapy cycle or completion of sequential thoracic radiotherapy. The samples were collected 2 weeks after relapse had been diagnosed by imaging and before administration of the second-line chemotherapy. The sampling date could be adjusted depending on the type of treatment and the visit schedule, with allowance for ± 2 weeks. Reevaluations of the disease status were conducted using the same techniques as those applied at the baseline, every 8 to 12 weeks, depending on the type of treatment the patient had received and the treatment schedule. Disease status was assessed according to the RECIST¹⁸ by examiners with no knowledge of the CTC levels. Serum lactate dehydrogenase (LDH) levels and the levels of other biomarkers, including neuron-specific enolase (NSE) and progastrin-releasing peptide (ProGRP), were measured at the same time point as the baseline CTC measurement. The blood samples for the serum biomarker measurements were obtained by venous puncture, and the sera were stored at -40°C until use. The ProGRP concentration was measured using an ELISA kit (FUJIREBIO Inc., Tokyo, Japan), and the NSE concentration was measured using the radioimmunoassay solid-phase method (SRL Inc., Tokyo, Japan).

Counting of CTCs

Blood samples were drawn into 10-ml vacuum tubes (CellSave, Immunicon, Huntingdon Valley, PA). Samples were maintained at room temperature, mailed overnight, and processed within 96 hours of collection. The results were reported quantitatively as the number of CTCs per 7.5 ml of blood. All CTC evaluations were performed without knowledge of the patient clinical status in one of two laboratories (Hyogo College of Medicine, Japan, or the laboratory of SRL Inc.). The CellSearch system was used for the CTC counting, the technical details of which, including accuracy, precision, linearity, and reproducibility, have been previously described.³ CTCs were defined as EpCAM-isolated intact cells showing positive staining for cytokeratin and negative staining for CD45. At each time point, the favorable and unfavorable groups were defined as those with CTC levels less than or more than or equal to the selected threshold, respectively.

Statistical Analysis

The primary analysis was a comparison of the OS between the unfavorable and favorable groups stratified according to the selected threshold of CTC level. The study was designed to enroll 50 patients for a statistical power of 80% with a two-sided log-rank test at a level of 0.05 to detect an absolute difference of 40% points between the two groups in the 1-year estimates of OS (20% in the unfavorable group versus 60% in the favorable group). To select the threshold CTC level that most clearly distinguished patients with an unfavorable prognosis from those with a favorable prognosis, thresholds of 1 to 100 cells at baseline were systematically correlated with the OS. The Cox proportional hazard ratio (HR), goodness-of-fit, and discriminatory power of each threshold were compared. The Bonferroni correction was applied for multiple testing for 14 thresholds, and a p value of < 0.0036 was set to obtain a statistical significance of $p < 0.05$. The goodness-of-fit of the model was assessed by the coefficient of determination (R^2) defined as $1 - \{(\log \text{likelihood of the estimated model}) / (\log \text{likelihood of the model with only the intercept})\}$. The discriminatory power was assessed by the accuracy rate ([AR] defined as the rate of correct diagnosis among all predictions of 1-year survivors) and the area under the receiver operator characteristics curve (AUROC). The treatment-free interval (TFI) was defined as the time between the completion of first-line chemotherapy and the diagnosis of relapse. Patients with a TFI of 90 days or more were considered to have treatment-sensitive disease, and those with a TFI of less than 90 days were considered to have treatment-refractory disease. For all survival analyses, the time to death was defined as the time between the date when the blood sample was obtained and the date of death or date of the last follow-up visit. Separate Kaplan-Meier survival plots were generated based on the CTC levels at baseline and the results in the follow-up blood collections. Survival curves were compared using the log-rank test. Cox proportional hazards regression was used to determine the HRs for the OS adjusted for age, gender, pretreatment stage (extensive disease [ED] versus limited disease [LD]), and ECOG-PS at the time of blood collection. The discriminatory power of the baseline CTC, LDH, NSE, and ProGRP for predicting 1-year survivors was compared by AUROC. The χ^2 test or Fisher exact test was used to compare categorical variables. For comparison of the means, the nonparametric Wilcoxon's test or analysis of variance was used. We tested the correlations between variables by calculating the Spearman's rank correlation coefficients. Calculations were carried out using the statistical program, JMP version 9.0 for Windows (SAS Institute Inc., Cary, NC).

RESULTS

Patient Characteristics

In total, 51 consecutive patients met the inclusion criteria and were prospectively enrolled between July 2009 and September 2010. The cutoff date for analysis was August 31, 2011. The median age of the patients was 67 years, and 44 of the patients (86.3%) were men (Table 1). Nineteen of the

TABLE 1. Baseline Characteristics

Characteristics	All (n = 51)	Extensive Disease (n = 24)	Limited Disease (n = 27)
Age, median (range)	67 (34–92)	66.5 (57–80)	68 (34–92)
Gender (female:male)	7:44	3:21	4:23
ECOG-PS, n (%)			
0	21 (41.2)	6 (25.0)	15 (55.6)
1	21 (41.2)	10 (41.7)	11 (40.7)
2	9 (17.6)	8 (33.3)	1 (3.7)
No. of organs with metastasis, median (range)	0.5 (0–3)	1 (0–2)	None
Brain metastasis, n (%)	7 (13.7)	7 (29.2)	None
Liver metastasis	8 (15.7)	8 (33.3)	None
Bone metastasis	3 (5.9)	3 (12.5)	None
Malignant effusion	12 (23.5)	11 (45.8)	1 (3.7)
Serum biomarkers (mean ± SE)			
NSE (ng/ml)	75.7 ± 24.3	131.2 ± 49.5	26.4 ± 5.5
ProGRP (pg/ml)	657.2 ± 205.7	1071.3 ± 419.1	289.0 ± 66.7
LDH (IU/L)	360.5 ± 79.9	529.7 ± 164.4	210.1 ± 8.8
Treatments, n (%)			
Chemotherapy alone	32 (62.7)	24 (100.0)	8 (29.6)
Chemoradiotherapy	19 (37.3)	None	19 (70.4)
Regimens, median cycle (range)	4 (1–6)	4 (1–6)	4 (1–5)
Cisplatin + etoposide, n (%)	23 (45.1)	16 (66.7)	7 (25.9)
Carboplatin + etoposide	21 (41.2)	2 (8.3)	19 (76.4)
Cisplatin + irinotecan	7 (13.7)	6 (25.0)	1 (3.7)

ECOG-PS, Eastern Cooperative Oncology Group performance status; SE, standard error; NSE, neuron-specific enolase; ProGRP, progastrin-releasing peptide; LDH, lactate dehydrogenase.

27 patients with LD had received chemoradiotherapy, while the remaining 8 patients could not receive radiotherapy for the following reasons and were treated by chemotherapy alone. The first patient was a 73-year-old man with a treatment history of thoracic chemoradiotherapy for esophageal cancer 6 years before the current treatment. Reirradiation was avoided because of the potential late adverse effects of radiotherapy. The second patient was a 79-year-old man with poor pulmonary functions who was scheduled for sequential radiotherapy after chemotherapy. However, his tumor progressed, with the development of contralateral pulmonary metastases after the first course of chemotherapy, and radiotherapy could not be administered. The remaining six patients had interstitial lung disease before the start of the treatment. Thoracic radiotherapy was withheld because of the potential risk of severe radiation pneumonitis. Twenty-four patients (47.1%) were still alive at the time of analysis. The median follow-up period for determining the survival was 13.0 months after the baseline blood sample collection. All 51 patients were evaluable for the baseline CTC level. Blood samples were not obtained during follow-up from two pa-

tients who died of interstitial lung disease and cancer progression. The remaining 49 patients were evaluable for the posttreatment CTC levels. The median time between the baseline and posttreatment blood collections was 3.4 months. Thirty-eight patients (74.5%) exhibited tumor progression; 37 were evaluable for the CTC level at the time of relapse, and 1 woman refused to provide blood samples.

Circulating Tumor Cells

Two or more CTCs were detected in 68.6% of the patients (95% confidence interval [CI], 55.0–79.7) at baseline, in 26.5% of the patients (95% CI, 16.2–40.3) posttreatment, and in 67.6% of the patients (95% CI, 51.5–80.4) at the time of relapse (Table 2). The CTC counts at baseline were higher in patients with ED, who showed a median of 9.5 cells (range, 0–5648), than in those with LD, who showed a median of 1 cell (range, 0–58; $p = 0.0001$, Figure 1A). Fourteen of the 16 patients (87.5%) who had a baseline CTC level of ≤ 1 had LD. The median CTC levels at baseline in patients with 0, 1, and ≥ 2 organs showing metastases were 2.0 (range, 0–58), 7.5 (1–799), and 21.0 (0–5648), respectively, showing a statistically significant correlation of the CTC count with the number of organs showing metastases (Spearman's rho, 0.72, $p < 0.0001$, Figure 1B). Patients with liver metastasis had higher CTC levels than those without liver metastasis (64 [range, 5–5648] versus 3 [range, 0–799]; $p = 0.0007$). There was no association between brain or bone metastasis and the CTC levels (data not shown).

Stratification According to Levels of Circulating Tumor Cells

The baseline CTC level was predictive of the OS when it was stratified by the threshold of 8 cells ($p = 0.0029$; Table 3). The Cox proportional HR signifying the difference between the unfavorable (more than or equal to threshold) and favorable (less than threshold) groups showed a waxing and waning pattern with the peak at the level of 8 CTCs. The HR associated with a CTC level of 8 cells was 3.50 (95% CI, 1.45–8.60) after adjustment for stage (ED or LD), age, gender, and ECOG-PS at the baseline. The Cox proportional hazard model at this level also showed a favorable goodness-of-fit and discriminatory power with the highest R^2 , AR, and AUROC among all the thresholds examined. Thus, a cutoff level of 8 CTCs was chosen for the subsequent analyses. Analyses based on the stage (ED or LD) and therapy type

TABLE 2. CTC Levels at the Baseline, Posttreatment, and at the Time of Relapse

	Baseline	Posttreatment	At Relapse
Total ^a	51	49	38
Evaluable ^b	51	49	37
CTC, median (range)	4 (0–5648)	0 (0–253)	1 (0–510)
CTC, mean ± SE	203.2 ± 118.5	10.2 ± 5.9	44.6 ± 16.8
CTC ≥ 2 , % (95% CI)	68.6 (55.0–79.7)	26.5 (16.2–40.3)	67.6 (51.5–80.4)

^a Number of patients alive and evaluable.

^b Number of patients with nonmissing data for CTCs at the time-point indicated. CTC, circulating tumor cell; SE, standard error; CI, confidence interval.




FIGURE 1. Box plots were drawn using the minimum and maximum values and the 25th, 50th, and 75th percentiles. *A*, Circulating tumor cell (CTC) levels at the baseline and the disease stage. ED, extensive disease; LD, limited disease. *B*, CTC levels at the baseline and number of metastatic organs. *C*, CTC levels at the baseline and the timing of blood sampling. *p* values calculated by Wilcoxon's test and analysis of variance (ANOVA) are presented.

TABLE 3. Baseline CTC and Prognosis

CTC Level ^a	Adjusted HR (95% CI) ^b	<i>p</i> ^c	<i>R</i> ²	AR	AUROC (95% CI)
1	0.74 (0.26–2.40)	0.0604	0.06	0.49	0.55 (0.43–0.65)
2	0.67 (0.25–1.87)	0.0532	0.06	0.51	0.55 (0.42–0.67)
3	0.76 (0.27–2.11)	0.0606	0.06	0.55	0.58 (0.45–0.71)
4	0.85 (0.25–2.79)	0.0656	0.05	0.61	0.63 (0.48–0.75)
5	1.59 (0.61–4.29)	0.0481	0.06	0.67	0.68 (0.53–0.80)
6	2.97 (1.24–7.31)	0.0063	0.08	0.73	0.73 (0.58–0.84)
7	2.97 (1.24–7.31)	0.0063	0.08	0.73	0.73 (0.58–0.84)
8	3.50 (1.45–8.60)	0.0029	0.09	0.76	0.74 (0.59–0.85)
9	2.90 (1.20–7.04)	0.0072	0.08	0.73	0.71 (0.57–0.83)
10	2.41 (0.99–5.81)	0.0151	0.07	0.71	0.69 (0.54–0.80)
15	3.00 (1.19–7.40)	0.0079	0.08	0.71	0.68 (0.54–0.79)
25	2.02 (0.74–5.04)	0.0318	0.06	0.67	0.62 (0.50–0.73)
50	3.49 (1.23–9.79)	0.0107	0.08	0.67	0.62 (0.50–0.72)
100	3.97 (0.90–15.59)	0.0181	0.07	0.65	0.58 (0.48–0.67)

^a CTC levels are expressed as the number of cells per 7.5 ml of blood.

^b The Cox proportional hazard ratios were adjusted for stage, age, gender, and ECOG-PS at the baseline.

^c The level of significance calculated by the Bonferroni method was $p < 0.0036$.

HR, hazard ratio; CTC, circulating tumor cell; CI, confidence interval; AR, accuracy rate for predicting 1-year survivors; AUROC, area under the receiver operator characteristics curve for predicting 1-year survivors.

(chemotherapy alone or chemoradiotherapy) showed that the prognostic significance of the CTC level was significant only in the ED subset and in the patients treated by chemotherapy alone (Supplemental Table 1, Supplemental Digital Content 1, <http://links.lww.com/JTO/A204>).

Baseline CTC and Prognosis

Figure 2A shows the Kaplan-Meier curves for the OS according to the baseline CTC levels. Patients in the unfavorable group had significantly shorter survival than those in

the favorable group ($p = 0.0014$). The 1-year survival rates and the median OS in the unfavorable and favorable groups were 31.6% versus 78.0% and 8.5 versus 17.2 months, respectively. The sensitivity, specificity, AR, and AUROC for predicting 1-year survivors using the cutoff level of 8 CTCs were 0.81, 0.65, 0.75, and 0.73 (95% CI, 0.58–0.84), respectively. The 1-year survival rates in the unfavorable and favorable groups were 21.4 and 70.0% ($p = 0.0282$), respectively, in the ED subset, and 60.0 and 81.6% ($p = 0.4387$), respectively, in the LD subset (Figures 2B, C).

Posttreatment CTC and Prognosis

During the posttreatment period, the CTC levels were measured in the 49 patients who were available for the evaluation. Of these 49 patients, 7 (14.3%) with ≥ 8 CTCs had a significantly shorter posttreatment survival than the remaining 42 (85.7%) with < 8 CTCs ($p = 0.0096$, Figure 2D). The HR of the threshold CTC count adjusted for stage, age, and posttreatment PS was 2.76 (95% CI, 0.97–6.92, $p = 0.0562$). The median posttreatment survivals in the unfavorable and favorable groups were 4.1 and 13.9 months, respectively. At the time of relapse, CTC levels were measured in 37 patients. Of these 37 patients, the 13 (35.1%) with ≥ 8 CTCs had a significantly shorter postrelapse survival than the remaining 24 (64.9%) with < 8 CTCs ($p < 0.0001$, Figure 2E). The HR of the threshold CTC adjusted for stage, age, TFI (< 90 versus ≥ 90 days), and PS at the time of relapse was 6.20 (95% CI, 2.39–17.52, $p = 0.0002$). The median postrelapse survivals in the unfavorable and favorable groups were 4.0 and 11.8 months, respectively.

Posttreatment CTC Status and Prognosis

Among the 42 patients with posttreatment CTC levels of < 8 , 29 had a baseline CTC level also of < 8 (group A), and in the remaining 13, the baseline CTC level was ≥ 8 (group B). Among the seven patients with posttreatment CTC levels of ≥ 8 (group C), four had a baseline CTC level also of ≥ 8 , and the remaining three had a baseline CTC level of < 8 . As shown in Figure 3, the survival impact of conversion from an unfavorable to favorable CTC level was assessed by using the Kaplan-Meier curve for posttreatment survival according to the posttreatment CTC status. The median posttreatment survival was > 18.8 months in group A, 7.2 months in group B, and 4.1 months in group C ($p = 0.0066$). The difference in the survival between group A and group C was significant ($p = 0.0047$ by log-rank test; level of significance calculated by the Bonferroni method, $p = 0.0166$). Conversely, there was no significant difference between group A and group B ($p = 0.0288$), or group B and group C ($p = 0.2489$). The HR adjusted for the pretreatment stage, posttreatment ECOG-PS, and TFI was 3.08 (95% CI, 1.03–8.90; $p = 0.0450$) in group B and 3.29 (95% CI, 1.01–10.07; $p = 0.0479$) in group C, both calculated using group A as the reference (Table 4).

Discriminatory Power of CTCs and Serum Biomarkers for Predicting the Prognosis

Figure 4 shows the receiver operator characteristics curves for CTCs, and the serum levels of LDH, NSE, and ProGRP measured at the baseline. Data on survival at 1 year




FIGURE 2. Kaplan-Meier curves for overall survival in patients with <8 and ≥8 circulating tumor cells (CTCs) at the baseline in the full set of data (A), extensive disease subset (B), and limited disease subset (C). Kaplan-Meier curves for posttreatment survival and postrelapse survival in patients with <8 and ≥8 CTCs posttreatment and at relapse (D and E). *p* values calculated by the log-rank test are presented.




FIGURE 3. Kaplan-Meier curves for posttreatment survival in three groups, including patients in whom the baseline and posttreatment circulating tumor cell (CTC) levels remained at <8 (group A), patients in whom the CTC level converted from ≥8 to <8 cells (group B), and patients in whom the posttreatment CTC level was ≥8 cells (group C). *p* values calculated by the log-rank test are presented.

TABLE 4. Hazard Ratios of the Posttreatment Status of CTC Level

Posttreatment CTC Status	CTC Level ^a	n	MST (mo)	Adjusted HR (95% CI) ^b	<i>p</i>
Group A	<8-<8	29	NR	Reference	
Group B	≥8-<8	13	7.2	3.08 (1.03-8.90)	0.0450
Group C	≥8-≥8 or <8-≥8	7	4.1	3.29 (1.01-10.07)	0.0479

Group A: patients whose baseline and posttreatment CTC levels remained <8 cells; group B: patients whose CTC level converted from ≥8 to <8 cells; and group C: patients whose posttreatment CTC level was ≥8 cells.

^a CTC levels are expressed as the number of cells per 7.5 ml of blood.

^b The Cox proportional hazard ratios were adjusted for the pretreatment stage, posttreatment ECOG-PS, and treatment-free interval.

CTC, circulating tumor cell; HR, hazard ratio; MST, median survival time; CI, confidence interval; NR, not reached.

were available for all 51 patients. The baseline CTC level showed a favorable discriminatory profile, showing an AUROC of 0.70 (95% CI, 0.52-0.83), as compared with that of 0.67 (0.49-0.82) for LDH, 0.68 (0.52-0.82) for NSE, and 0.46

(0.29–0.64) for ProGRP. The differences in the AUROC among the parameters were not significant ($p = 0.1044$).

Radiologic Response and Changes in the CTC Levels

Assessment of the best radiologic response to the first-line treatment was performed using the RECIST criteria in 50 patients. One man died of interstitial lung disease before the follow-up imaging study. Figure 5 shows the baseline and posttreatment CTC levels in patients showing complete re-

sponse (CR, $n = 6$), partial response (PR, $n = 27$), stable disease (SD, $n = 5$), and progressive disease (PD, $n = 12$). There was no significant difference between the CR/PR subsets and SD/PD subsets in the baseline CTC (median, 4 [range, 0–1683] versus 4 [range, 0–5648]; $p = 0.7337$ by the Wilcoxon’s test) or posttreatment CTC (0 [0–44] versus 0.5 [0–253]; $p = 0.3370$) level. The numbers of patients with undetectable posttreatment CTCs or patients with lower post-treatment CTC levels than the baseline CTC levels were 4 (66.7%) in the CR group, 24 (88.9%) in the PR group, 4 (80.0%) in the SD group, and 7 (58.3%) in the PD group, with no significant differences among the groups showing the various treatment responses ($p = 0.2878$ by the χ^2 test).

DISCUSSION

This study is the first prospective evaluation of the optimal CTC cutoff to predict the OS in patients with chemotherapy-naive SCLC. First, we showed that the CTC level was strongly predictive of the OS, especially in the ED subset. Then, an optimal cutoff level, CTC count of ≥ 8 cells per 7.5 ml of blood was identified by comparing the Cox proportional HRs of various CTC levels for the OS. This cutoff level was also found to be valid for predicting the posttreatment survival and postrelapse survival in the same cohort. We also showed that the baseline CTC level had a high discriminatory power, similar to the serum NSE and LDH.

Circulating SCLC cells have been reported to show high expression levels of EpCAM,¹⁹ which has been used as a key marker to isolate CTCs using the CellSearch system. The appropriateness of using the CellSearch system for detecting circulating SCLC cells was previously assessed by Hou et al.¹⁶ They showed that 15 CTC samples obtained from patients with SCLC by the CellSearch system were neuroendocrine in nature (CD56 positive) and confirmed their neoplastic origin by immunohistochemical comparison of these cells with the cells obtained from matched tumor biopsy specimens. The detection rate (≥ 2 CTCs per 7.5 ml blood) of circulating SCLC cells by the CellSearch system in cases of SCLC is reportedly quite high, being 67 to 86%,^{8,16} as compared with that in cases with other tumors with metasta-




FIGURE 4. Receiver operator characteristics curve analysis for predicting 1-year survivors. The area under the curve is 0.70 (95% confidence interval [CI], 0.52–0.83) for the circulating tumor cell (CTC) level at baseline, 0.67 (95% CI 0.49–0.82) for serum lactate dehydrogenase (LDH) at baseline, 0.68 (95% CI 0.52–0.82) for serum neuron-specific enolase (NSE) at baseline, and 0.46 (95% CI 0.29–0.64) for serum progastrin-releasing peptide (ProGRP) at baseline.




FIGURE 5. Relationship between radiologic response and the changes in the circulating tumor cell (CTC) level. A, Baseline and posttreatment CTC levels in patients showing PD (solid line) and SD (dotted line). B, Baseline and posttreatment CTC levels in patients showing PR (solid line) and CR (dotted line). PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response.

ses.^{3,7,11,15} Consistent with these reports, the detection rate in the SCLC patients in our study was 68.6%. Given that approximately half of our patients had nonmetastatic disease, we consider that CTCs are detected in a high percentage of cases of SCLC. Higher CTC counts have been reported as an indicator of the presence of distant metastases, such as bone metastasis in prostate cancer²⁰ and liver metastasis in colorectal cancer.¹¹ In patients with NSCLC, the CTC levels reportedly correlated with the number of organs showing metastatic involvement, and higher CTC levels are predictive of liver and bone metastasis.¹⁵ Our results also showed an association between the CTC levels and the presence of metastasis, especially to the liver.

The CTC cutoff level (8 CTCs per 7.5 ml of blood) in our study to discriminate between groups with a favorable and unfavorable prognosis was higher than that reported for other tumors. In metastatic breast cancer, the cutoff level of 5 was chosen by comparing the median PFS and the Cox proportional HR for each threshold from 1 to 10,000 CTCs. The same cutoff was also shown to be correlated with the OS.⁷ The cutoff of five cells was then applied to metastatic castration-resistant prostate cancer and was well validated to be predictive of the OS.¹⁴ In metastatic colorectal cancer, the cutoff level of three cells was chosen by correlating the baseline CTC level with the response at the first follow-up imaging study. The cutoff level was well validated to be predictive of both the OS and PFS in a subsequent validation cohort.¹¹ Our cutoff level was based on a comparison of the Cox proportional HR for OS. The differences in the cutoff levels may be attributable to the statistical method used for choosing the optimal cutoff level or might reflect the highly metastatic potential of SCLC itself. In addition, we observed the prognostic significance of the baseline CTC only in the ED subset or patients treated by only chemotherapy in the subset analyses. As the previous studies in other malignancies have been conducted only in patients with metastatic disease, another study for ED-SCLC will be required to validate our results.

Conversion from an unfavorable baseline CTC level to a favorable follow-up CTC level reportedly has a strong impact on the survival. Patients with such conversion showed a favorable OS, statistically similar to that in patients with a persistent favorable CTC level in breast, prostate, and colorectal cancers.^{7,11,14} In contrast, our study showed a relatively small impact of such conversion on the survival in SCLC patients. This difference might reflect the nature of SCLC itself, known to be aggressive and to rarely be in a dormant state.^{2,3} A lower CTC level might be an appropriate treatment goal if minimal residual cancer cells after treatment had a larger impact on the survival in SCLC patients. Chemotherapeutic agents active against SCLC are as yet limited, and the classic platinum doublet with etoposide or irinotecan remains the standard first-line treatment regimen. Treatment options for relapsed SCLC are further limited to several cytotoxic agents,^{21,22} and no molecular-targeted agents have yet been approved.²³ These limitations in treatment modalities might be related to the small impact of conversion after first-line treatment. NSE and ProGRP are commercially available

serum biomarkers and are used as markers for monitoring of SCLC patients. They have been reported to be highly sensitive and specific for the diagnosis of SCLC, and elevated levels of these markers at baseline have been shown to be associated with poor prognosis.^{24–26} LDH has also been reported to have prognostic significance in patients of SCLC.²⁷ We showed that the baseline CTC level showed a good discriminatory power for predicting the prognosis in SCLC patients, similar to serum NSE and LDH, and furthermore, that the baseline CTC level was probably a better predictor of survival than the serum ProGRP, by receiver operator characteristics curve analysis.

The treatment response was reported to be associated with the CTC level at the time of imaging in breast cancer.²⁸ In colorectal cancer, the CTC level measured 3 to 5 weeks after the initiation of therapy had a relatively low sensitivity (27%) for predicting PD.¹¹ In our study, we found no correlation between the results of the response assessment using the RECIST criteria and the baseline CTC level, posttreatment CTC level, or change in the CTC level associated with treatment. The changes in the tumor size might not always be related to the changes in the outflow of tumor cells from the tumors.

The major limitation of this study was that the study population was small. The threshold value was derived from a cohort at a single institution and not validated in an independent validation cohort. In addition, our study included not only patients receiving chemotherapy alone but also patients treated by chemoradiotherapy. Because the treatment goals are different for chemotherapy and chemoradiotherapy, that is, palliation versus cure, separate derivation studies will be required to choose the optimal CTC cutoff level.

There has been an increasing interest in several aspects of CTCs. First, measurement of the CTC levels has been expected to guide decision making, such as determining the timing of changing, continuing, or discontinuing the current treatment, or identifying appropriate candidates for adjuvant chemotherapy.^{29–31} Second, CTC analysis is anticipated to provide samples for biomarker analysis. Monitoring of human EGFR-related 2-positive CTCs in breast cancer patients during human EGFR-related 2-targeted therapy^{32–34} and analysis of androgen receptor gene alterations in the CTCs of prostate cancer patients^{35,36} have been reported. In addition, the newly developed CTC analyzer shows a high detection power for CTCs and was used for the analysis of *EGFR*-gene alterations in the CTCs from patients with NSCLC.^{37,38} These studies have established a new role for CTC analysis as a noninvasive method of tumor profiling or target monitoring during treatment with molecular-targeted agents. Although few molecular-targeted agents currently available are active against SCLC, the high detection rate of CTCs in cases of SCLC might provide an opportunity for the screening of active drugs and accelerate the development of new therapeutic strategies.

In conclusion, this study showed that CTCs are readily detectable by the CellSearch system in patients with SCLC and that the CTC levels before and after treatment had strong

prognostic significance. A large prospective multiinstitutional validation study is required to confirm our results.

ACKNOWLEDGMENTS

The authors thank Hiroaki Akamatsu, MD, Satoru Miura, MD, Madoka Kimura, MD, Rieko Kaira, MD, Sakae Morii, MD, Chikara Sakaguchi, MD, Hirofumi Eida, MD, Yoko Toda, MD, and Akihiro Tamiya, MD, for their constructive advice and provision of patients for this study.

REFERENCES

- Jackman DM, Johnson BE. Small-cell lung cancer. *Lancet* 2005;366:1385–1396.
- Krug LM, Kris MG, Travis WD. Small cell and other neuroendocrine tumors of the lung. In DeVita VT, Lawrence TS, Rosenberg SA (Eds.). *CANCER Principles and Practice of Oncology*, 8th Ed. Philadelphia: Lippincott Williams & Wilkins, 2008. Pp. 946–963.
- Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. *Clin Cancer Res* 2004;10:6897–6904.
- Fetsch PA, Cowan KH, Weng DE, et al. Detection of circulating tumor cells and micrometastases in stage II, III, and IV breast cancer patients utilizing cytology and immunocytochemistry. *Diagn Cytopathol* 2000;22:323–328.
- Loberg RD, Fridman Y, Pienta BA, et al. Detection and isolation of circulating tumor cells in urologic cancers: a review. *Neoplasia* 2004;6:302–309.
- Molnar B, Sipos F, Galamb O, et al. Molecular detection of circulating cancer cells. Role in diagnosis, prognosis and follow-up of colon cancer patients. *Dig Dis* 2003;21:320–325.
- Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. *N Engl J Med* 2004;351:781–791.
- Tanaka F, Yoneda K, Kondo N, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer. *Clin Cancer Res* 2009;15:6980–6986.
- Kagan M, Howard D, Bendele T, et al. A sample preparation and analysis system for identification of circulating tumor cells. *J Clin Ligand Assay* 2002;25:104–110.
- Riethdorf S, Fritsche H, Muller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. *Clin Cancer Res* 2007;13:920–928.
- Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. *J Clin Oncol* 2008;26:3213–3221.
- Cohen SJ, Punt CJ, Iannotti N, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. *Ann Oncol* 2009;20:1223–1229.
- Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. *J Clin Oncol* 2005;23:1420–1430.
- de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. *Clin Cancer Res* 2008;14:6302–6309.
- Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. *J Clin Oncol* 2011;29:1556–1563.
- Hou JM, Greystoke A, Lancashire L, et al. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. *Am J Pathol* 2009;175:808–816.
- Wu C, Hao H, Li L, et al. Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. *J Thorac Oncol* 2009;4:30–36.
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228–247.
- Kularatne BY, Lorigan P, Browne S, et al. Monitoring tumour cells in the peripheral blood of small cell lung cancer patients. *Cytometry* 2002;50:160–167.
- Scher HI, Jia X, de Bono JS, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. *Lancet Oncol* 2009;10:233–239.
- Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. *J Clin Oncol* 2008;26:5401–5406.
- von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. *J Clin Oncol* 1999;17:658–667.
- Puglisi M, Dolly S, Faria A, et al. Treatment options for small cell lung cancer - do we have more choice? *Br J Cancer* 2010;102:629–638.
- Nisman B, Biran H, Ramu N, et al. The diagnostic and prognostic value of ProGRP in lung cancer. *Anticancer Res* 2009;29:4827–4832.
- Wójcik E, Kulpa JK, Sas-Korczyńska B, et al. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. *Anticancer Res* 2008;28:3027–3033.
- Shibayama T, Ueoka H, Nishii K, et al. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). *Lung Cancer* 2001;32:61–69.
- Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. *J Clin Oncol* 1991;9:1618–1626.
- Liu MC, Shields PG, Warren RD, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. *J Clin Oncol* 2009;27:5153–5159.
- Lin H, Balic M, Zheng S, et al. Disseminated and circulating tumor cells: role in effective cancer management. *Crit Rev Oncol Hematol* 2011;77:1–11.
- Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. *Cancer Biol Ther* 2007;6:308–312.
- Wicha MS, Hayes DF. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. *J Clin Oncol* 2011;29:1508–1511.
- Fehm T, Muller V, Aktas B, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. *Breast Cancer Res Treat* 2010;124:403–412.
- Ignatiadis M, Rothe F, Chaboteaux C, et al. HER2-positive circulating tumor cells in breast cancer. *PLoS One* 2011;6: e15624.
- Riethdorf S, Muller V, Zhang L, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. *Clin Cancer Res* 2010;16:2634–2645.
- Jiang Y, Palma JF, Agus DB, et al. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. *Clin Chem* 2010;56:1492–1495.
- Leversha MA, Han J, Asgari Z, et al. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. *Clin Cancer Res* 2009;15:2091–2097.
- Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. *N Engl J Med* 2008;359:366–377.
- Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. *Nature* 2007;450:1235–1239.

Phase I Clinical Study of the Angiogenesis Inhibitor TSU-68 Combined with Carboplatin and Paclitaxel in Chemotherapy-Naive Patients with Advanced Non-small Cell Lung Cancer

Isamu Okamoto, MD, PhD,* Hiroshige Yoshioka, MD,† Koji Takeda, MD,‡
Miyako Satouchi, MD, PhD,§ Nobuyuki Yamamoto, MD, PhD,|| Takashi Seto, MD,¶
Kazuo Kasahara, MD, PhD,# Masaki Miyazaki, MD, PhD,* Ryuichi Kitamura, PhD,**
Akio Ohyama, PhD,** Noriko Hokoda, BS,†† Hiroshi Nakayama, MS,†† Eiji Yoshihara, MS,††
and Kazuhiko Nakagawa, MD, PhD*

Introduction: TSU-68 is an oral small-molecule inhibitor that targets vascular endothelial growth factor receptor 2, platelet-derived growth factor receptor β , and fibroblast growth factor receptor 1. An open-label, single-arm, phase I study was performed to evaluate escalating doses of TSU-68 in combination with standard chemotherapy in patients with advanced non-small cell lung cancer.

Methods: Eligible patients received TSU-68 at 200 or 400 mg twice daily and continuously in combination with carboplatin (area under the curve, 6 mg \cdot min/mL) plus paclitaxel (200 mg/m²) on day 1 every 21 days.

Results: Thirty-seven patients were enrolled at the two dose levels of TSU-68. No dose-limiting toxicities were observed with TSU-68 at the 200 mg twice a day dose level. At 400 mg twice a day, one of six patients experienced a dose-limiting toxicity (anorexia of grade 3) during the first cycle. The 400 mg twice a day dose level was determined to be the recommended dose, and a total of 34 patients were treated at this dose. Overall, adverse events were mild to moderate in severity, with the most frequently observed such events being myelosuppression, neuropathy, and gastrointestinal disorders. No drug-related bleeding was observed. The objective response rate

was 39.4% (95% confidence interval, 22.9–57.9%), and median progression-free survival was 5.6 months (95% confidence interval, 3.6–7.2 months). Coadministration of TSU-68, carboplatin, and paclitaxel had no substantial impact on the pharmacokinetics of these drugs.

Conclusions: TSU-68 can be safely combined with standard doses of carboplatin-paclitaxel, with the combination manifesting promising antitumor activity.

Key Words: Non-small cell lung cancer, Angiogenesis, Phase I.

(*J Thorac Oncol.* 2012;7: 427–433)

Lung cancer is the leading cause of death related to cancer worldwide, with non-small cell lung cancer (NSCLC) accounting for 85% of lung cancer cases.¹ For individuals with advanced or metastatic NSCLC, platinum-based chemotherapy is the mainstay of first-line treatment on the basis of the moderate improvement in survival and quality of life it affords compared with best supportive care alone.² There is thus still a need for new treatment regimens to improve the outcome for patients with advanced NSCLC.

Angiogenesis, the formation of new blood vessels from a preexisting vasculature, is essential for tumor growth and metastasis.^{3,4} Receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and fibroblast growth factor receptors (FGFRs), together with their corresponding ligands, play key roles in angiogenesis.^{3,4} The addition of bevacizumab, a monoclonal antibody specific for VEGF, to carboplatin-paclitaxel was shown to result in a 2-month increase in median overall survival in individuals with advanced nonsquamous NSCLC.⁵ In a confirmatory study, the addition of bevacizumab to cisplatin-gemcitabine resulted in a significant improvement in progression-free survival (PFS), but the overall survival benefit did not achieve statistical significance.^{6,7} These observations provide a rationale for combining an angiogenesis inhibitor with conventional cytotoxic chemotherapy in individuals with ad-

*Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka; †Department of Respiratory Medicine, Kurashiki Central Hospital, Okayama; ‡Department of Medical Oncology, Osaka City General Hospital, Osaka; §Department of Thoracic Oncology, Hyogo Cancer Center, Hyogo; ||Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka; ¶Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka; #Department of Respiratory Medicine, School of Medicine, Kanazawa University Hospital, Ishikawa; **Pharmacokinetics Research Laboratory; and ††Clinical Development I Department, Taiho Pharmaceutical Co. Ltd., Tokyo, Japan.

Disclosure: Ryuichi Kitamura, PhD, Akio Ohyama, PhD, Noriko Hokoda, BS, Hiroshi Nakayama, MS, and Eiji Yoshihara, MS, are employees of Taiho Pharmaceutical Co., Ltd.

Address for correspondence: Isamu Okamoto, MD, PhD, Department of Medical Oncology, Kinki University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-Sayama, Osaka 589-8511, Japan. E-mail: chi-okamoto@dotd.med.kindai.ac.jp

Copyright © 2012 by the International Association for the Study of Lung Cancer

ISSN: 1556-0864/12/0702-0427

vanced NSCLC, although the application of such a combination is currently limited by the risk of life-threatening hemoptysis and is not indicated in patients with squamous cell histology.⁵

TSU-68 (Taiho Pharmaceutical Co. Ltd., Tokyo, Japan) is an orally available, small-molecule inhibitor that targets VEGFR2, PDGFR β , and FGFR1.^{8,9} TSU-68 has been shown to inhibit the growth of and to reduce vessel density in human tumor xenografts subcutaneously implanted in nude mice.⁹⁻¹² Additional preclinical data suggest that the effect of TSU-68 on vascular endothelial cells is enhanced in combination with paclitaxel, resulting in greater antitumor activity than that observed with either agent alone.¹³ Phase I studies of TSU-68 monotherapy in patients with advanced and heavily pretreated malignancies have determined the recommended dose (RD) to be up to 400 mg twice daily administered orally and continuously, with the most frequently encountered adverse events (AEs) being mild gastrointestinal toxicities such as anorexia and diarrhea.^{14,15} We now describe a phase I study of TSU-68 in combination with standard carboplatin-paclitaxel chemotherapy as first-line treatment for patients with advanced NSCLC.

PATIENTS AND METHODS

Patients

Eligible patients met the following criteria: a diagnosis of NSCLC confirmed either histologically or cytologically, a clinical stage of IIIB not amenable to curative treatment or of stage IV, no previous chemotherapy (prior adjuvant chemotherapy was permitted if completed ≥ 180 days before enrollment), an age of 20 to 74 years, an Eastern Cooperative Oncology Group performance status of 0 or 1, a projected life expectancy of at least 3 months, and adequate hematologic, hepatic, and renal function. Patients were excluded if they had symptomatic brain metastasis, a history of drug allergy, malignant ascites requiring drainage, treatment with any investigational drug within 4 weeks before study enrollment, or severe medical conditions such as uncontrolled hypertension, myocardial infarction, unstable angina pectoris, or infection with fever. Pregnant or breast-feeding women were also excluded. All patients provided written informed consent to participate in the study, which was conducted in accordance with good clinical practice guidelines and was approved by the Institutional Review Board of each center.

Study Design and Treatment

This was an open-label phase I study of TSU-68 in combination with carboplatin and paclitaxel in chemotherapy-naïve patients with advanced NSCLC. The study consisted of two steps. The objectives of the first, dose-escalation step were to determine the RD of TSU-68 in this regimen and pharmacokinetics. If a dose-limiting toxicity (DLT) was not observed in any of the first three patients, the dose was escalated to the next level. If a DLT was observed in one of the first three patients, three additional patients were recruited to that dose level. If fewer than two of the first six patients experienced a DLT in the first cycle, the dose level was to be recommended for the second step. The primary objective of

the second step was to evaluate treatment feasibility at the RD by determining the proportion of patients who received more than 50% of the planned dose of TSU-68 within the first three cycles. The sample size at the RD was determined to be 30 with a one-sided alpha of 2.5% and a power of 90%; the expected and threshold values were 66.7 and 33.3%.

Patients were premedicated before intravenous paclitaxel administration for 3 hours at a dose of 200 mg/m² followed by intravenous administration of carboplatin for 1 hour at an area under the curve (AUC) of 6 mg \cdot min/mL on day 1 of each 3-week cycle. TSU-68 was administered orally twice daily at either 200 or 400 mg for 21 consecutive days. Patients who discontinued the chemotherapy could continue treatment with TSU-68 alone until disease progression or the development of unacceptable toxicity.

Safety and Efficacy Assessment

Patients were evaluated for AEs during therapy and for 28 days after administration of the last dose of the study treatment. Toxicity was evaluated according to the National Cancer Institute Common Toxicity Criteria version 3. A DLT was defined as any of the following adverse drug reactions: neutropenia of grade 4 for ≥ 7 days, thrombocytopenia of grade 4, febrile neutropenia, or a nonhematologic toxicity of grade ≥ 3 with the exception of diarrhea, nausea, vomiting, hyponatremia, or hypokalemia, each of grade 3.

Antitumor activity was assessed radiologically (computed tomography or magnetic resonance imaging) every 6 weeks. All responses were defined according to the RECIST 1.0.¹⁶ If a patient was documented as having a complete response (CR) or a partial response (PR), a confirmatory evaluation was performed after an interval of 4 weeks. Disease control was defined as the best tumor response among CR, PR, or stable disease (SD) that was confirmed and sustained for 6 weeks or longer. PFS was defined as the time from the date of registration to the date of the detection of progressive disease or of death from any cause, and it was assessed by the Kaplan-Meier method.

Pharmacokinetics

Pharmacokinetics were analyzed during the first cycle of treatment in nine patients enrolled in the first step. Blood samples were sequentially collected until 11 hours after the first dose on days 1 and 2 for TSU-68, 24 hours after infusion for carboplatin, and 48 hours after infusion for paclitaxel. The concentrations of TSU-68, carboplatin-derived free platinum, and paclitaxel in plasma were determined by validated bio-analytic methods. The following pharmacokinetic parameters were calculated from the plasma concentration data by non-compartment analysis: maximum plasma concentration (C_{max}), time of C_{max} (t_{max}), terminal half-life ($t_{1/2}$), and AUC for TSU-68 and total clearance (CL_{tot}), and distribution volume at steady state ($V_{d,ss}$) for carboplatin and paclitaxel.

Assessment of Biomarkers

Blood samples were collected from patients at baseline and after each cycle of TSU-68 treatment in combination with carboplatin-paclitaxel, and plasma was isolated and stored at -70°C until analysis. The concentrations of VEGF-A,

VEGF-C, soluble VEGFR2, E-selectin, PDGF-AA, PDGF-BB, acidic FGF, and basic FGF were quantified with the use of enzyme-linked immunosorbent assay kits (R&D Systems, Minneapolis, MN). All samples were analyzed in duplicate. Changes in biomarker concentrations from baseline were evaluated with the exact paired Wilcoxon test (two-sided). A *p* value of <0.05 was considered statistically significant.

TABLE 1. Characteristics of the Study Patients (*n* = 37)

Parameter	No.	Percentage
Sex		
Male	21	56.8
Female	16	43.2
Age (yr)		
Median		64.0
Range		42–74
Stage		
IIIB	5	13.5
IV	28	75.7
Recurrent	4	10.8
Histology		
Adenocarcinoma	29	78.4
Squamous	5	13.5
Other	3	8.1
ECOG performance status		
0	14	37.8
1	23	62.2

ECOG, Eastern Cooperative Oncology Group.

RESULTS

Patient Characteristics

Thirty-seven patients were enrolled at seven clinical sites in Japan between February and October 2009. Characteristics of the 37 enrolled subjects are summarized in Table 1. Twenty-one patients were male and 16 were female. The median age was 64 years (range, 42–74 years). The most common histology was adenocarcinoma (29 patients, or 78.4%), followed by squamous cell carcinoma (5 patients, or 13.5%); three patients who had unspecified NSCLCs were classified as “other.”

Dose Escalation and DLTs

No DLT was observed in the first three patients treated with 200 mg of TSU-68 twice daily and so the dose was escalated to the second level of 400 mg twice daily. Given that one of the first three patients experienced a DLT (anorexia of grade 3) at 400 mg of TSU-68 twice daily, three additional patients were accrued. None of these additional patients developed a DLT, and the dose of 400 mg of TSU-68 twice daily was therefore determined as the RD.

Drug Delivery

A total of 34 patients were treated with 400 mg of TSU-68 twice daily combined with paclitaxel at 200 mg/m² and carboplatin at an AUC of 6 mg · min/mL. The median number of cycles of carboplatin-paclitaxel delivered was 3 (range, 1–6). The median relative dose intensities were 83.7% for paclitaxel and 92.4% for carboplatin, with dose reductions for these drugs often being a result of neuropathy. Thirty-two patients (94.1%) received more than 50% of the planned TSU-68 dose within the first three cycles, achieving the defined criterion of treatment feasibility. The median




FIGURE 1. Patient disposition. ALT, alanine aminotransferase; AST, aspartate aminotransferase.